Omega Diagnostics Share Discussion Threads

[rheiner] 04/4/2007 09:54

The reported three sales so far today are actually buys.

[smiler 0] 04/4/2007 09:47

Agree, But I can not see why the Drop ?? But I will be buying a few !!

[rheiner] 04/4/2007 08:46

Only about 123m in issue and less than a penny to buy. Surely worth a punt ?

[gadg3t] 08/3/2007 14:16

guman, I would like to think so, there products are excellent in the diagnosis of infectious diseases,
particularly Syphilis, TB and Dengue Fever,and product range covers a wide application area. I think they just need to get noticed, I think (HOPE) WE will see an up in April !! I have sent today an e mail to the CEO WILL post his reply . I am happy to wait, my ave is now 1.80 but a tic up soon would be nice !!

[guman] 08/3/2007 09:56

is there any hope for this company to do anything to move sp(up).
hold 200k@2.8?

[the mullah] 27/2/2007 00:51

We are watching.

[gadg3t] 26/2/2007 20:03

New sight is up and running , link is now on header. I still hold and IMHO ONE to watch.

[guman] 26/2/2007 09:33

is there anything likely to happen,no news of anykind for 3 months.

[gadg3t] 20/12/2006 20:32

they have a new web page under construction should be up and running by Jan 2007,

[adorling] 20/12/2006 07:29

Can someone tell me the URL address for the web page please?

[alftupper] 20/12/2006 05:31

One to watch me thinks - underperformance of the share price has led to a significant buying opportunity

[gadg3t] 06/11/2006 20:42

Arab Lab, Dubai 2007 Date:30/10/2006
We are pleased to confirm our participation at the forthcoming Arab Lab Exhibition in Dubai between 11/14 February 2007. Our stand location will be part of the Al Nawras booth 213.

We very much look forward to welcoming you to our stand and seeing you in Dubai.

Omega Marketing

[gadg3t] 06/11/2006 20:22

LONDON (AFX) - Shares in Omega Diagnostics Group jumped in opening deals as the market reacted positively to news that the group has received a European patent for its branched peptide technology, boosting the shares up 0.38 pence to 2.00.

[e-mail]

hco/vjt

LONDON (AFX) - Omega Diagnostics Group PLC said it has been granted a European patent for its branched peptide technology, which has been exclusively licensed from the Medical Research Council.

The company said the technology is currently being applied to a new test for

Herpes Simplex Virus 2 and has been shown to be effective in increasing the efficacy of other tests such as Human Immunodeficiency Virus (HIV).

[e-mail]

mar/wj

[gadg3t] 06/11/2006 20:20

Omega Diagnostics Group PLC
06 November 2006


Omega Diagnostics Group PLC

European patent grant

Omega Diagnostics Group PLC is pleased to announce that a European Patent
(0994121) has been granted in respect of its Branched Peptide technology which
has been exclusively licensed from the Medical Research Council (MRC). The
Patent covers the enabling technology that allows assays to be developed with
resulting superior sensitivity and specificity, which are key features of any
new diagnostic test. The technology is currently being applied to a new test for
Herpes Simplex Virus 2 (HSV-2) and it has already shown to be effective in
increasing the efficacy of other tests such as Human Immunodeficiency Virus
(HIV)


In addition to the grant of the Branched Peptide Patent in Europe, a US Patent
(5,965,357) has already been granted in respect of the specific peptide sequence
for HSV-2 which means that the intellectual property aspect of this development
is well covered for the future.


HSV is a chronic disease that infects over 1 billion people worldwide. It is
also estimated that there are over 60 million adults in the US infected with
HSV-2 and because HSV-2 is difficult to diagnose, the need for more accurate
diagnosis is acute.



This information is provided by RNS
The company news service from the London Stock Exchange

[smiler 0] 31/10/2006 17:07

I think so too, I have a small holding, lets hope things pick up, a lot of potential !! :)

[alftupper] 31/10/2006 16:59

Well worth looking at they have got distribution productd and revenues generating a modest profit = one to watch

[gadg3t] 16/10/2006 17:04

A broker trade to day thats about all, still waiting to get noticed ! But one to watch and IMHO worth a small punt !!!

[gadg3t] 16/10/2006 15:45

Cannon why cant you get permission ? spent all your money on ERX

[gadg3t] 16/10/2006 13:37

Well cannon, ODX ARE now in to there 2nd month now as ODX and when you look at there Products and the fact they are now into manufacturing & Development distributing to over 100 countries I dont think they are short of customers !! + There Sub Operations

[cannoncan] 16/10/2006 13:09

gadg, I cant buy these, I cant get permission

[gadg3t] 16/10/2006 12:53

SUBSIDIARY OPERATIONS (ODX)

Cardiopath Limited was formed in 1999 to license and commercialise a new diagnostic test for Atherosclerosis and Coronary Heart Disease that has been developed by a German/ Hungarian research consortium. Commercialisation partners are being sought worldwide both on a territory and equipment specific basis.
Initial clinical trial data show the test to be highly predictive for the onset of acute Coronary Heart Disease.This product detects a new marker for Cardiovascular Risk Assessment and is a breakthrough in identifying the onset of Atherosclerosis and Coronary Heart Disease. It has an excellent correlation with traditional risk markers and has a multiple assay format potential. Initial clinical trial data show the test to be highly predictive for the onset of acute Coronary Heart Disease. Commercialisation partners are being sought worldwide both on a territory and equipment specific basis.

.We also sell our products through OEM arrangements with other manufactures of diagnostic products in selected territories.

[gadg3t] 16/10/2006 12:32

LAST RNS

Omega Diagnostics Group PLC
04 October 2006

4 October 2006

Omega Diagnostics Group PLC

Issue of equity

Omega Diagnostics Group PLC (the 'Company') confirms it has issued 881,250 new
ordinary shares of 1p each in the Company ('Ordinary Shares') at a price of 2p
per share to Beachcroft LLP, a law firm, and 587,500 new Ordinary Shares at a
price of 2p per share to City Financial Associates Limited, the Company's
nominated adviser. These shares are being allotted in reflection of advisory
services provided to the Company (previously named Quintessentially English PLC)
in connection with an earlier aborted potential acquisition.

Application has been made for these shares to be admitted to trading on AIM and
admission is expected to occur on 9 October.


Still waiting on e mail to check KEY DATA is up to date !!

[gadg3t] 16/10/2006 12:20

KEY DATA:
Omega Diagnostics Group PLC Ticker: ODX
Exchanges: LON
0 Sales: 0
Currency: Pounds Sterling
Fiscal Year Ends: December
Share Type:
Country: United Kingdom
Major Industry: Financial
Sub Industry: Investment Companies
Employees: N/A
Market Capitalization: 3,196,646
Total Shares Outstanding: 121,777,000
Closely Held Shares: 6,666,665

Board of Directors
Chairman David Evans
Managing Director Andrew Shepherd
Finance Director Kieron Harbinson
Non-Executive Director Bill Logie

[gadg3t] 16/10/2006 12:18

Omega Diagnostics Group PLC Formerly known as Quintessentially English PLC.

Omega is a biotechnology company that manufacturers and develops quality, diagnostic products for use in hospitals, clinics and laboratories worldwide. We are based in Scotland in the United Kingdom and we have a subsidiary company, CardioPath Ltd based in the UK developing novel diagnostic tests for Cardiovascular Disease.


Founded in the UK by Mr Andrew Shepherd, in 1987, Omega has been involved with the manufacture and development of in vitro diagnostic test kits exporting 98% of all manufactured products. Omega's distribution network extends to over 100 countries worldwide and the Company was awarded the Queen's Award for Export Achievement in 1993. As well as many other business awards since then. See Company achievements.

Omega was accredited ISO 9001 Certification in June 1997.

In looking to the future, Omega invests continuously in the Research and Development of new products and systems. Omega Diagnostics : Diagnosis is the essential first step in the prevention of disease. The essential first step in the alleviation of suffering and saving lives.

Our Ideal is swift and accurate diagnosis, available to all, world-wide.

Our Commitment is to the relentless pursuit of that ideal. To invest continuously in biotechnological research and development. To create new products and new systems. To constantly improve.

The Reality is Omega Diagnostics. Providing quality diagnostic products to hospitals, clinics and laboratories in over 100 countries - promptly delivered and competitively priced. Providing full sales and technical support. Providing the essential first step.

Omega Diagnostics specialises in the diagnosis of infectious diseases, particularly Syphilis and TB, and for this reason we have dedicated two sections of this website to information on these diseases. You can also see information on the range of Omega's quality diagnostic products by going to the 'Product Range' section.
For ease of reference, there is a link to Omega's extensive 'Product List' in every section of this module.

Cardiopath Limited, Omega's subsidiary company involved in leading edge research into cardiovascular diagnostics and therapeutic developments, is also included on the Omega Website.

The Share Price 2.38 Mid when thread started





Omega Diagnostics Gr Omega Diagnostics buys Genesis, Cambridge Nutritional for 6.7 mln stg